Novartis Tumor 8 new special drugs shortlisted for China's first provincial-level special drug insurance.

On August 2nd, China's first provincial-level custom-made Huimin-type global special drug insurance - Lecheng Global Special Drug Insurance, in Hainan Free Trade Port Boao Lecheng Global Special Drug Insurance Launch Conference and "Lecheng All Health" Insurance Summit announced the official launch. The new insurance covers 70 special drugs, involving 35 major types of malignant tumors and 2 rare diseases, Novartis Tumor (China) 8 new special drugs were selected.Vice Governor Wanglu, Hainan Province, , met with Novartis Cancer (China) General Manager Ji Bicheng
in June this year, Lecheng International Medical Tourism Leading Zone
Advance Zone announced the first batch of 100 kinds of new anti-tumor drugs and rare disease drugs, half of which have not yet been listed in China, representing the international cutting-edge drug research results.
Novartis Oncology has nine new special drugs included in the first batch of introductions, including drugs that are not listed in the country and products that have been listed in China but partially adapted have not yet been approved or not covered in health insurance. Currently, Piqray and Tabrecta in Lecheng are about to be used in the treatment of breast and non-small cell lung cancer patients in the country, respectively.
to achieve medical technology, equipment, drugs and international advanced level by 2025, "three synchronization" is the goal of Lecheng's first area. "Lecheng Global Special Drug Insurance" is the first area of Lecheng to achieve the "three synchronization" of drugs and international advanced level of the development of health insurance innovation products, aimed at reducing the medical burden of low- and middle-income families in the country through commercial insurance to enable the global innovative drugs can more widely benefit Chinese patients.
this time selected "Lecheng Global Special Drug Insurance" Novartis Cancer New Drug .